Sickle Cell Disease Clinical Trial
Official title:
Niacin Therapy to Improve Endothelial Function in Sickle Cell Disease
This study will determine whether niacin can improve blood flow in people with sickle cell
disease, in which abnormal red blood cells interfere with blood flow to cause the disease
symptoms. Niacin, a drug that has been used to increase HDL (good cholesterol) levels,
improves blood flow in people without sickle cell disease. This study will see if it can do
the same in people with the disease.
Patients with sickle cell disease between 18 and 65 years of age may be eligible for this
study.
Candidates are screened with a medical history, physical examination, blood tests,
echocardiogram and 6-minute walk test of exercise capacity.
Participants have the following baseline blood flow studies:
- Flow-mediated dilation (FMD): An ultrasound picture of the artery in the forearm is
obtained. A blood pressure cuff is then placed on the upper arm and inflated for 5
minutes. After the pressure cuff is released, the ultrasound is repeated.
- Peripheral artery tonometry (PAT): A sensor is placed on the subject s finger. The
sensor puts pressure on the finger and measures blood flow.
- Standard forearm blood flow test: Small tubes are placed in the artery of the forearm at
the inside of the elbow. Saline is infused into one tube. Pressure cuffs are applied to
the wrist and upper arm. A strain gauge (rubber band device) is placed around the
forearm. When the cuffs are inflated, blood flows into the arm, stretching the strain
gauge, and the flow measurement is recorded. Blood samples are collected from the tube
in the artery to measure blood counts, proteins and other chemicals. At various times,
small doses of the following drugs are administered through the tube in the vein:
- Sodium nitroprusside causes blood vessels to dilate and increases blood flow to the
heart.
- Acetylcholine causes blood vessels to dilate and slows heart rate.
- LNMMA decreases blood flow by blocking the production of nitric oxide.
Blood flow is measured after each dose of the different drugs. There are rest periods between
injections of the different drugs. Pictures of the forearm are taken during the studies using
an infrared camera and computer.
-Drug Treatment. Participants are assigned to take three 4-week courses of niacin or placebo.
They return to the Clinical Center at the following intervals from the time they start the
test drug for followup:
- Weeks 2, 6 and 10: Brief medical history, review of medication side effects and blood
tests.
- Weeks 4 and 8: Physical examination, brief medical history, review of medication side
effects and blood tests, repeat FMD and PAT blood flow studies and 6-minute walk test.
- Week 12: Same as weeks 4 and 8 plus standard blood flow studies and echocardiogram.
Sickle cell disease is an autosomal recessive disorder and the most common genetic disease
affecting African-Americans. Approximately 0.15 percent of African-Americans are homozygous
for sickle cell disease, and 8 percent have sickle cell trait. Hemoglobin S polymerization
leads to red cell rigidity, microvascular obstruction, inflammation, and end-organ ischemic
injury. Our published data indicate that up to 50 percent of sickle cell patients have
vascular dysfunction due to impaired bioavailability of endogenous nitric oxide, due in large
part to scavenging of nitric oxide by cell-free hemoglobin. We recently have completed
studies that directly demonstrate endothelial dysfunction in patients with sickle cell
disease, characterized by decreased ACh dependent vasorelaxation in forearm blood flow
studies, distinct from the nitric oxide resistance above. Further, we have found in sickle
cell patients a new association between low levels of apoA-I, pulmonary hypertension and
endothelial dysfunction. Raising levels of HDL, and therefore apoA-1, could have the effect
of ameliorating the endothelial dysfunction characteristic of sickle cell disease by
affecting endothelium dependent vasorelaxation. Therapies directed at restoring HDL in these
patients may be beneficial.
HDL is thought to promote vascular health in a variety of ways, some of which are unrelated
to lipid transport. One of the best-known mechanisms relates to efflux of cholesterol from
atherosclerotic plaque, yet HDL is thought to have several antithrombotic and
anti-inflammatory effects. In vitro HDL attenuates formation of oxidized LDL and inhibits
endothelial cell expression of inflammatory cell adhesion molecules. It is also thought to
mediate NO production via stimulation of eNOS, thereby modulating endothelial function. In a
study of subjects with atherosclerosis, low HDL levels correlated with impaired vasomotor
relaxation via brachial artery FMD. Another study utilizing recombinant HDL cholesterol
infused into brachial arteries of hypercholesterolemic men resulted in increased
acetylcholine mediated blood flow that was inhibited by the infusion of L-NAME, an eNOS
inhibitor, suggesting that HDL increased blood flow via an eNOS dependent mechanism. This may
have implications not only for subjects with atherosclerosis, but also for those with sickle
cell disease and endothelial dysfunction.
We propose that niacin therapy could improve vascular reactivity in response to
acetylcholine. Several options for increasing HDL levels have been previously utilized in
forearm flow studies using venous occlusion plethysmography or flow-mediated dilation.
Reconstituted HDL (rHDL), apoA-1 mimetics and niacin therapy were all shown to improve
endothelial dysfunction, and proved safe and effective.
This trial will aim to 1) establish the effects of niacin treatment on raising HDL levels in
subjects with sickle cell disease, 2) investigate whether niacin treatment would result in
improvement of endothelial-dependent relaxation via venous occlusion plethysmography, and 3)
compare the efficacy of peripheral arterial tonometry measurements to venous occlusion
plethysmography and flow-mediated dilation as indicators of vascular dysfunction.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02227472 -
Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease
|
||
Recruiting |
NCT06301893 -
Uganda Sickle Surveillance Study (US-3)
|
||
Recruiting |
NCT04398628 -
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
|
||
Completed |
NCT02522104 -
Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH)
|
Phase 4 | |
Recruiting |
NCT04688411 -
An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease
|
N/A | |
Terminated |
NCT03615924 -
Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease
|
Phase 3 | |
Not yet recruiting |
NCT06300723 -
Clinical Study of BRL-101 in Severe SCD
|
N/A | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Completed |
NCT04917783 -
Health Literacy - Neurocognitive Screening in Pediatric SCD
|
N/A | |
Completed |
NCT04134299 -
To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease
|
N/A | |
Completed |
NCT02580565 -
Prevalence of Problematic Use of Equimolar Mixture of Oxygen and Nitrous Oxide and Analgesics in the Sickle-cell Disease
|
||
Recruiting |
NCT04754711 -
Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition
|
N/A | |
Completed |
NCT04388241 -
Preliminary Feasibility and Efficacy of Behavioral Intervention to Reduce Pain-Related Disability in Pediatric SCD
|
N/A | |
Recruiting |
NCT05431088 -
A Phase 2/3 Study in Adult and Pediatric Participants With SCD
|
Phase 2/Phase 3 | |
Completed |
NCT01158794 -
Genes Influencing Iron Overload State
|
||
Recruiting |
NCT03027258 -
Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome
|
N/A | |
Withdrawn |
NCT02960503 -
Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02620488 -
A Brief Laboratory-Based Hypnosis Session for Pain in Sickle Cell Disease
|
N/A | |
Withdrawn |
NCT02630394 -
A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease
|
Phase 1 | |
Completed |
NCT02567682 -
Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy Subjects
|
Phase 1 |